THURSDAY | JULY 30, 2020
How Did Sweden Flatten Its Curve Without a Lockdown?
— One expert credits a "good-enough strategy"; others worry that it won't last

Despite never implementing a full-scale lockdown, Sweden has managed to flatten its curve, prompting its health leadership to claim victory -- but others question the cost of the strategy, as the country has a far higher death toll than its Scandinavian neighbors.

In late July, Sweden's  7-day moving average of new cases  was about 200, down from a peak of around 1,140 in mid-June. Its  daily death totals  have been in the single digits for two weeks, well below its mid-April peak of 115 deaths in a single day.
However, on a per-capita basis, Sweden far outpaces its Scandinavian neighbors in COVID deaths, with 567 deaths per million people compared with Denmark's 106 deaths per million, Finland's 59 deaths per million, and Norway's 47 deaths per million. The Swedish figure is closer to Italy's 581 deaths per million.


READ MORE MEDPAGE TODAY
ASIPP® Annual Meeting 2020 Goes Virtual
 
Due to unavoidable circumstances related to COVID-19, ASIPP is transitioning its annual meeting scheduled September 4-6, 2020, in Dallas, Texas to a virtual meeting. This will provide you with many advantages:
 
  • Save time and money: More time in the office with patients and no fear of Covid exposure.
  • Attend the meeting from wherever you want.
  • Get back on track with your CMEs.
  • Revisit the sessions and explore exhibit booths even after the meeting ends. Virtual platform access will remain open until the summer of 2021.
  • Same great networking opportunities in virtual platform: Ability to host and request private meetings; talk with others while you visit exhibit booths, and so much more!
  • Still offering world-renowned speakers on relevant subjects to IPM, COVID-19 interfacing with IPM, and many other subjects including opioids and regenerative medicine.
  • Meeting kicks off with a presentation by a well-known figure in the industry, Randy Alvarez, President and CEO of Wellness Hour.
 
 
If you have already registered for the Annual Meeting, your registration fee has been transferred to the Virtual Annual Meeting. There is nothing you need to do now. You will receive information on how to attend the meeting in August.
 




Order Now - Recorded Virtual Review Courses


The following courses are offered:


  • Documentation, Coding, Compliance, and Practice Management Review Course
  • Controlled Substance Management Review Course
  • *Pain Medicine and Interventional Pain Management Comprehensive Review Course

*not available until the end of the live course July 26, 2020
ABIPP Recognizes Your Knowledge and Expertise
 
The  American Board of Interventional Pain Physicians  ( ABIPP ) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become  ABIPP  certified.
 
ABIPP  now offers the only competency
certification program for regenerative medicine.

For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org  or call 270-554-9412 x4217 or by email at  summer@asipp.org .

TESTS OFFERED
 
ABIPP Part I  - Theoretical written exam - TBD
 
ABIPP Part II  - Oral and Hands-on practical exam - TBD
 
ABIPP Competency Exam  - includes written, oral, and hands-on practical examinations TBD
 
Combined CSM/CCPM Exam for ABIPP Path  – TBD
 
Competency Exam in Controlled Substance Management – TBD
 
Competency Exam in Coding, Compliance, and Practice Management -  TBD
 
Regenerative Medicine Competency Exam  - includes written, oral, and hands-on practical examinations – TBD
Pandemic Spike in Telehealth Levels Off
— But still significantly up among Medicare patients, HHS says

Telehealth's early bonanza during the pandemic has given way to persistently elevated use in primary care, a Department of Health and Human Services (HHS) report showed.
Analysis of Medicare fee-for-service (FFS) data showed an increase in Medicare primary care visits from 0.1% of all primary care in February to  43.5% in April , representing an increase from about 2,000 to 1.28 million telehealth visits per week.

Meanwhile, there was a "precipitous" drop in in-person visits for primary care in mid-March as COVID-19 took hold in the U.S., then a rise from mid-April through May, according to the report from the Office of the Assistant Secretary for Planning and Evaluation.



READ MORE | MEDPAGE TODAY |
Officials: Fraudulent Products Still Plague COVID-19 Supply Chain
— States, providers inadvertently buying "fake, faulty, and even illicit medical supplies "

WASHINGTON -- The domestic supply chain for personal protective equipment (PPE) and other products related to COVID-19 needs to be made more secure in order to avoid problems with fraudulent products, hoarding, and price gouging, members of a key Senate panel said Tuesday.

"Before the coronavirus pandemic, hospitals and healthcare workers could avoid purchasing counterfeits by tapping into tried-and-true supply chains," 



READ MORE | MEDPAGE TODAY |
July/August 2020
Issue Available
In this issue, Pain Physician includes Systematic Reviews on Interlaminar Epidural Injections, the Scrambler Therapy, and Long-term Outcomes of Epidurals for Lumbar Disc Hernation; Randomized Trials on Bilateral Ultrasound-Guided Erector Spine Plane Block and Contrast Medium Volume needed for Transforaminal Epidural Injections, and more.
FDA Requires Labeling Changes for Opioids to Include Information About Naloxone

The Food and Drug Administration (FDA) has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to include new recommendations about naloxone to the prescribing information.
Naloxone is an opioid antagonist indicated for the complete or partial reversal of opioid depression, and for the diagnosis of suspected or known acute opioid overdose. There are currently 3 FDA-approved formulations of naloxone: a nasal spray, an injectable, and an auto-injector.

The FDA has recommended the new labeling change to reduce the risk of death from opioid overdose by increasing access to naloxone. For patients who are prescribed opioid pain relievers or medicines to treat OUD, health care professionals are recommended to discuss the availability of naloxone, and should consider prescribing it to patients who are at increased risk of opioid overdose, including those taking  benzodiazepines  or CNS depressants, history of OUD, or history of opioid overdose. Patients at increased risk of overdose should be prescribed naloxone regardless of whether they are receiving a prescription for an opioid pain reliever or medicine for OUD. Health care professionals should also consider prescribing naloxone to patients with household members, including children, or other close contacts who are at risk for accidental ingestion or opioid overdose. 

READ MORE | CLINICAL PAIN ADVISOR |
We've Seen the COVID-19 Future and It Is Concerning
— A wide variety of symptoms seem to persist post-recovery

Forgive me if I take a moment, while I know so much of the rest of the country is suffering through the ongoing onslaught and devastation from COVID-19, to think about how we here in New York City are starting to see some unusual sequelae to this unfortunately fascinating infection.

As our numbers of acute active cases here have gone down, and providers are starting to take a deep breath and members of our community are starting to emerge, blinking at the bright light, from their home isolation, we've been noticing a lot of really interesting developments in many patients who had COVID-19 during our phase of the pandemic.

READ MORE | MEDPAGE TODAY |
‌
ASIPP ® Partners with Fedora Billing And Revenue Cycle Management Company  
ASIPP is now able to offer unique benefits for revenue cycle management with billing, etc.

Fedora is a company known to many of our board members and others. ASIPP ® has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis. 

You may view the ASIPP ® billing program website at the following link:   https://www.asippbilling.com/  

Some of the ASIPP ® Billing Program highlights are below:
Up to 50% savings for ASIPP ® members for their billing or revenue cycle management for their offices and surgery centers:
 
  • Expertise in interventional pain management billing for all types of services
  • 99% Clearing House Rate
  • 95% First-Time Claim Passage
  • 23.4 Average Days in A/R
  • Eligibility and Benefits Verification 
  • Pre-Certification/Prior Authorization
  • Denials and A/R Management 

VIEW THE ASIPP® BILLING PROGRAM | CLICK HERE |
Join The Group Purchasing
Organization Today
ASIPP ® has formed a partnership with Henry Schein and PedsPal , a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.

It will be easy for  ASIPP ® members in good standing to enroll today and begin to realize the savings this partnership can bring. Members can join or see sample prices by going to   http://pedspal.org/asipp/default.html    

Click on “view our discounted supplier prices” (Username: ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!

LEARN MORE ABOUT GROUP PURCHASING | CLICK HERE |
CMS Updates Data on COVID-19 Impacts on Medicare Beneficiaries

On July 28, CMS released its first monthly update of data that provides a snapshot of the impact of COVID-19 on the Medicare population. For the first time, the snapshot includes data for American Indian/Alaskan Native Medicare beneficiaries. The new data indicate that American Indian/Alaskan Native beneficiaries have the second highest rate of hospitalization for COVID-19 among racial/ethnic groups after Blacks. Previously, the number of hospitalizations of American Indian/Alaskan Native beneficiaries was too low to be reported.

The updated data confirm that the COVID-19 public health emergency is disproportionately affecting vulnerable populations, particularly racial and ethnic minorities. This is due, in part, to the higher rates of chronic health conditions in these populations and issues related to the social determinants of health.
The updated data on COVID-19 cases and hospitalizations of Medicare beneficiaries covers the period from January 1 to June 20, 2020. It is based on Medicare claims and encounter data CMS received by July 17, 2020.

Other key data points:
  • Black beneficiaries continue to be hospitalized at higher rates than other racial and ethnic groups, with 670 hospitalizations per 100,000 beneficiaries
  •  Beneficiaries eligible for both Medicare and Medicaid – who often suffer from multiple chronic conditions and have low incomes – were hospitalized at a rate more than 4.5 times higher than beneficiaries with Medicare only (719 versus 153 per 100,000)
  • Beneficiaries with end-stage renal disease continue to be hospitalized at higher rates than other segments of the Medicare population, with 1,911 hospitalizations per 100,000 beneficiaries, compared with 241 per 100,000 for aged and 226 per 100,000 for disabled
  • CMS paid $2.8 billion in Medicare fee-for-service claims for COVID-related hospitalizations, or an average of $25,255 per beneficiary

READ MORE | CMS |

RESOURCE RECOVERY & TRADING LLC, is voluntarily recalling all the lots manufactured by MXL Comercial S.A. de C.V. of Hand Sanitizer with the next information: HAND SANITIZER 70% Ethyl Alcohol Disinfectant Gel, packaged in 6.7 FL Oz. (200 ml) bottles, UPC 650240026020 and HAND SANITIZER Non-sterile Solution 70% Topical Solution, packaged in 20L (5.28 Gal) liter plastic containers, UPC 37710600013 to the consumer level. The products are being recalled due to the potential presence of undeclared methanol (wood alcohol) and subpotency ethyl alcohol.

Risk Statement: The main concern with the use of hand sanitizer that is sub-potent for ethyl alcohol is the potential for decreased bactericidal and virucidal activity. Adverse health consequences can be related to increased infections. In addition substantial, undeclared methanol exposure, which has inferior antiseptic properties compared to ethanol, can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system or death. Although all persons using these products on their hands are at risk, young children who accidently ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning. To date, RESOURCE RECOVERY & TRADING LLC has not received any reports of adverse events related to this recall.


READ MORE | FDA |
Essentials of Regenerative Medicine in Interventional
Pain Management
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.

Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
| ORDER | Essentials of Regenerative Medicine in IPM
Control Your Waiting Room TV

Customized waiting room TV exclusively for ASIPP ® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
GET YOUR OWN LOBBY TV CHANNEL | CLICK HERE FOR ASIPP-TV |
STATE SOCIETY MEETINGS
Send in your state society meeting news to Holly Long , hlong@asipp.org
ASIPP ® | Pain Physician Journal | Phone | Fax | Email
STAY CONNECTED